A Study of Lebrikizumab in Patients with Chronic Obstructive Pulmonary Disease

Mise à jour : Il y a 5 ans
Référence : EUCTR2015-001122-42

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

• To evaluate the efficacy of lebrikizumab compared with placebo in improving lung function, as measured by the absolute change in pre-bronchodilator forced expiratory volume in one second (FEV1) in patients with COPD and a history of exacerbations in the biomarker-high group (elevated serum periostin and blood eosinophils) and biomarker low group.


Critère d'inclusion

  • Chronic Obstructive Pulmonary Disease (COPD)